Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corporation is discontinuing its Phase 3 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease after an interim analysis for the first 46 participants who completed the double-blind phase showed no sputum culture conversions, indicating futility.
The data safety monitoring board reviewed the results on November 8, 2025 and agreed with stopping the study; no safety issues were identified. MannKind plans to investigate the outcome and apply learnings to MNKD-102, a dry powder clofazimine formulation progressing from pre-clinical toward Phase 1.
MannKind Corporation reported Q3 2025 results with total revenue of $82,130,000, up from $70,079,000 a year ago. Net income was $7,985,000 (basic and diluted EPS $0.03), driven by higher product sales and royalties.
Revenue mix: product revenue $48,274,000, collaborations and services $26,506,000, and royalties $33,319,000. Operating income reached $18,896,000 as total expenses were $63,234,000. Other expense reflected an impairment of available-for-sale investment of $6,409,000.
On the balance sheet, cash and cash equivalents were $127,392,000 and short‑term investments were $132,643,000. A new term loan of $73,428,000 was outstanding. For the nine months, operating cash flow totaled $26,213,000. Stockholders’ deficit narrowed to $(44,552,000). After quarter end, MannKind completed the acquisition of scPharmaceuticals on October 7, 2025 following a $10,000,000 promissory note issued on August 24, 2025.
MannKind Corporation furnished a current report to announce that it issued a press release addressing results of operations and financial condition. The press release is included as Exhibit 99.1. This administrative update signals that the company has released its latest performance communication, with full details contained in the accompanying press release.
MannKind Corp (MNKD) reported an insider Form 4 for its EVP of Technical Operations. On 10/31/2025, the company withheld 17,071 shares of common stock in a transaction coded F, reflecting shares retained by the issuer to cover taxes upon vesting of previously reported RSUs at a price of $5.59 per share.
Following this tax-withholding event, the reporting person directly beneficially owns 473,988 shares of MannKind common stock.
Initial Form 3 filed for Ajay Ahuja reporting no beneficial ownership in MannKind Corp (MNKD). The filing lists Mr. Ahuja as Chief Medical Officer and a director/officer and notes the date of the triggering event as 09/29/2025. The form explicitly states No securities are beneficially owned and is signed on 10/09/2025. This is a routine Section 16 filing showing the officer currently holds no equity or derivative positions in the company.
MannKind Corporation entered into a merger agreement to acquire scPharmaceuticals, Inc. via a tender offer that began on September 8, 2025. The offer paid $5.35 in cash per scPharma share plus one non‑tradable contingent value right (CVR) per share that can pay up to $1.00 total if regulatory and sales milestones are met.
The CVRs pay up to $0.75 for FDA approval of an injection product by September 30, 2026 (reduced amounts for later approval) and up to additional payments tied to trailing 12‑month worldwide net sales of at least $110.0M (with full payment at $120.0M). Approximately 73.47% of scPharma shares were validly tendered by the offer's expiration, with guaranteed delivery notices for ~10.91% more; the merger closed by completing a short-form merger on October 7, 2025.
The acquisition was funded from available cash and borrowings under an amended credit facility that included an incremental delayed draw term loan commitment of $175.0M, and MannKind also funded debt extinguishment of approximately $82.6M. The amended credit terms include a pricing grid tied to a leverage test and an interest margin step‑up to 5.00% if net leverage reaches 5.00:1.00.
Stuart A. Tross, Chief People & Workpl Officer at MannKind Corp (MNKD), reported the sale of 47,000 shares on 09/16/2025 under a Rule 10b5-1 trading plan established June 17, 2025. The weighted average sales price was $5.34 per share (price range $5.33–$5.39). After the reported sale, Mr. Tross beneficially owned 1,032,013 shares. The filing is a routine Section 16 Form 4 disclosing an insider sale executed pursuant to a pre-established trading plan.
MannKind Corp (MNKD) reported a Form 144 notice indicating an intended sale of 47,000 common shares through Morgan Stanley Smith Barney LLC on 09/16/2025. The shares were acquired as performance shares from the issuer on 05/17/2024 and paid for on that date. The filing lists an aggregate market value of $250,792.00 for the shares and shows 306,828,335 shares outstanding, with no reportable sales by the same person in the past three months. The filer affirms no undisclosed material adverse information and includes the standard Rule 144 and 10b5-1 representations.
MannKind Corporation has expanded its long‑running collaboration with United Therapeutics through a first amendment to their 2018 global license and collaboration agreement. The amendment documents United Therapeutics’ decision to add an additional development product to the scope of the partnership.
MannKind will formulate an investigational molecule for this additional product using its Technosphere® platform and will supply specified quantities of clinical trial material, while United Therapeutics will handle all remaining preclinical and clinical development work. In return, MannKind will receive an upfront payment of $5 million, is eligible for up to $35 million in development milestone payments tied to the additional product, and would earn 10% royalties on its net sales if the product is ultimately approved.
MannKind Corporation disclosed a proposed transaction to acquire scPharmaceuticals through an Agreement and Plan of Merger and related tender offer documents. The deal contemplates contingent value rights (CVRs) with two milestone pools: Milestone 1 tied to delivery of SCP-111 via an autoinjector or West Pharma delivery system paying between $0.25 and $0.75 per CVR depending on achievement dates through June 30, 2027; Milestone 2 tied to 12‑month trailing worldwide net sales with up to $0.25 per CVR if $120.0 million in sales are achieved, and pro rata payments between $110.0 million and $120.0 million. The filing references an Amendment No.1 to a Loan Agreement to fund the transaction, a Form of Tender and Support Agreement, a press release and investor presentation as exhibits. The filing contains extensive forward‑looking statements about product launches, regulatory filings (including a planned supplemental NDA submission timing), clinical trials, commercialization strategy and risks, and lists conditions, representations, covenants, and termination rights governing the offer and merger.